Simponi golimumab regulatory update

FDA approved an sBLA from Johnson & Johnson for subcutaneous Simponi golimumab to treat moderately to severely active ulcerative colitis (UC) in adults who had an inadequate

Read the full 270 word article

How to gain access

Continue reading with a
two-week free trial.